|
Alteplase
resources
|
|
|
|
|
|
DRUG INFO
Alteplase
Drug Name:
Alteplase
Indication: For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
Pharmacology: Activase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.
Mechanism Of Action: Cleaves the Arg-Val bond in plasminogen to produce active plasmin.
Drug Category: Thrombolytic Agents
Brand Names/Synonyms: Tissue-type plasminogen activator precursor;tPA;t- PA;t-plasminogen activator;Alteplase;Reteplase; Activase (Genentech Inc)
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human tissue plasminogen activator
Chemical Formula: C2569H3928N746O781S40
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00050
CAS Registry Number: 105857-23-6
|
|
|
|
|
|
Alteplase News
(When available)
Nuvelo Surges On Alfimeprase Agreement For Up To $385M 05 Jan 2006
BioWorld Online (subscription), ...a clot within 15 minutes, Nuvelo's drug may have a significant advantage over the currently marketed product for CO, Cathflo Activase (alteplase, Genentech Inc ...
The clock is ticking for stroke patients 15 Jan 2006
USA Today Ten years ago, the stroke drug Activase was hailed as a medical breakthrough — the first treatment able to melt clots away and save the brain. ...
Nuvelo hopes two new drugs lead to company's first profit Jan 9, 2006
San Jose Business Journal, ...the body. Current treatments include a clot-busting drug made by South San Francisco's Genentech Inc. called Activase. But Nuvelo ...
Biotechnology Industry Veteran Richard Brewer Joins SRI ... Jan 9, 2006
Genetic Engineering News, As head of global product launches, he was responsible for growing the franchise for Activase(R), Genentech's blockbuster heart attack drug. ...
Nuvelo Surges On Alfimeprase Agreement For Up To $385M Jan 5, 2006
BioWorld Online (subscription), ...a clot within 15 minutes, Nuvelo's drug may have a significant advantage over the currently marketed product for CO, Cathflo Activase (alteplase, Genentech Inc ...
|
|
|
